BMY is here on the daily chart. The double top and death cross of the EMA moving averages makes for a strong candidate to short with shares or take put options. A comparsion of the most recent earnings report with the previous one sixty days earlier tells most of the story. The dual time frame RSI indicator shows ongoing wekaness. I will short BMY here and...
AMEX:PILL On the 4H Chart, current market price is sitting on the support of order blocks and the EMA200, while in an uptend from a double bottom in the sprint. It is moving into the high volume area of the voluxme profile. For the swing trade, the stop loss is $0.10 below the EMA200 while the targets are marked based on a combination of the horizontal...
STAA is a medical company specialized in implantable lenses. Many of those needing lens replacements for cataracts put things off during the COVID era and eye surgeons are now catching up on backed up patient loads. Medical insurance companies are burdened with patients catching up from the covid delays for elective surgeries. The surgeons and medical...
STRO on a 240 minute chart got trader interest out of earnings that were projected to be net cash outflow into reported actual earnings. This is a remarkable turnaround. The RSI lines surged. The predictive algorithm which relies on a lookback of the regression line for analysis toward the future forecasts a move up much higher. I will take a long trade here...
BCAB a medical technology penny stock had a good beat on earnings. This means the cash burn was only 70% of what was expected. On the strength of that traders reached. The indicators suggest more upside including RSI lines crossing over the 50 level and the MACD lines bouncing up on the approach to the zero horizontal line. The supply and demand...
XYNI is now ready to reverse long. I analyze this because ZYXI has dropped from overvalued and overbought through the fair value zone into undervalued territory in three trading days by viewing the anchored VWAP bands and the volume profile, The mean VWAP and POC line are confluent at 7.25. This is the logical first target. The MACD lines are negative 4X the...
We are traveling the bottom of the channel. I think it starts to move up shortly. Adolescent and Pediatric fixed dose phase 3 trials start this month and next month. FDA approval submission early/mid next year. Billion-dollar drug if it can get some funding? This is my own opinion, and you should not take any of this as financial advice.
pick your pill; yellow or blue? Which pattern are we possibly taking for a possible $32 end of bull run 2021 for ADA? Comment below.
On 6/11/2021 Piper Sandler brokerage Initiated Coverage giving a price target of $18.00 VXRT Vaxart today announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier. (prnewswire.com) This is in...
VXA-CoV2-1, Vaxart's experimental treatment for Covid-19 is unique in that it's a pill, not an injection. A pill would certainly be easier from a distribution and administration standpoint but also to get higher vaccination rates. On May 3, Vaxart's treatment showed demonstrable CD8 T-cell responses, but didn't produce high levels of neutralizing antibodies...
what we have to say... the blue pill or the red pill ?
Looks like we're seeing a trustworthy enough response from NEO after he got shot by the agents. lets hope he still knows kung fu. Gann angles are set u as resistances (didn't use box to reduce clutter), they will serve as the ascending channel's resistance on the uptrend top yellow line is target, bottom yellow line is next buy-in for the skeptics. ...